Inflectra (Infliximab)

Infliximab is a chimeric monoclonal antibody that specifically binds to tumor necrosis factor‑alpha (TNF‑α). By neutralising TNF‑α, it blocks a key pro‑inflammatory signaling pathway, thereby decreasing the immune‑mediated inflammation that drives the symptoms of the diseases it treats.

The dosing regimen for Inflectra is individualized by the prescribing clinician based on the patient’s condition, weight, and response to therapy. Healthcare professionals determine the infusion volume, frequency, and any dose adjustments according to approved clinical guidelines.

Safety data for infliximab in pregnancy and lactation are limited. The decision to use Inflectra during pregnancy or while breastfeeding should be made by a qualified healthcare provider after weighing potential benefits against possible risks to the mother and infant.

To place an order, submit an enquiry on the Inflectra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Inflectra is a biosimilar to the reference product Remicade and shares the same mechanism of action as other TNF‑alpha inhibitors such as adalimumab and etanercept. Clinical studies demonstrate comparable efficacy and safety, while offering potential cost advantages in many markets.

Inflectra must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Proper cold‑chain handling is essential to maintain product stability during transport and storage.

Inflectra is given as an intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically administered over a period of 2 hours, with the first dose given at week 0, followed by additional doses at weeks 2 and 6, and then every 8 weeks thereafter, as directed by the prescriber.

Serious risks include severe infections such as tuberculosis reactivation, opportunistic infections, new or worsening heart failure, demyelinating diseases, malignancies (especially lymphomas), and life‑threatening hypersensitivity reactions including anaphylaxis. Patients should be monitored closely for any signs of these conditions.

Inflectra is contraindicated in patients with known hypersensitivity to infliximab or any of its excipients, and in those with active serious infections. Caution is also advised for individuals with uncontrolled heart failure, a history of malignancy, or those receiving live vaccines.